Home / Stock ratings / eVTOL, Air Taxi and Logistics Stocks / RXO
Stock rating
RXO, Inc. (RXO) Stock Rating & Analysis
As of October 5, 2026, MELANY rates RXO, Inc. 60 out of 100 (Promising). Its highest factor score is price momentum at 84, and its lowest is valuation at 21.
MELANY ratingRated 2026-10-05RXO · composite score
Why RXO scores 60/100
RXO's 8 factor scores run from 21 to 84, and 3 of them sit above its composite of 60. Here is how RXO breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- Price +35.0% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 31 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How RXO compares
As of October 7, 2026, RXO, Inc. is tied for 8th of 20 in eVTOL, Air Taxi and Logistics Stocks, where the average score is 57.
Key risks for RXO
- Short interest 26% of float, high volatility risk on news
- High beta 2.0, amplifies market drawdowns 1.8x+ in selloffs
- Trading near 52-week high, limited upside without new positive catalyst
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
RXO, Inc. sits in the Industrials sector theme, which MELANY currently rates 10/100 for strength. Theme strength feeds RXO's momentum and catalyst factors above.
RXO trade plan (Pro)
MELANY has a full position plan for RXO, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates RXO
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. RXO, Inc.'s 60/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about RXO
Is RXO, Inc. (RXO) a buy?
As of 2026-10-05, MELANY rated RXO, Inc. Promising with a composite score of 60/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is RXO, Inc.'s MELANY score?
RXO, Inc. (RXO) has a MELANY composite score of 60/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the RXO stock rating calculated?
MELANY scores RXO from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy RXO, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates RXO, Inc. (RXO) Promising with a composite of 60/100 as of 2026-10-05. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the RXO stock price forecast?
MELANY does not publish price targets or forecasts for RXO. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 60/100 across eight factors for RXO, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is RXO stock overvalued or undervalued?
MELANY's valuation factor currently reads 21/100 for RXO, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives RXO's read.
What price should I buy RXO at?
Rather than chasing the current price, MELANY computes a smart entry zone for RXO: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying RXO stock?
The top risks MELANY currently flags for RXO, Inc.: Short interest 26% of float, high volatility risk on news; High beta 2.0, amplifies market drawdowns 1.8x+ in selloffs; Trading near 52-week high, limited upside without new positive catalyst; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is RXO, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 28/100 for RXO, Inc., and earnings track record, at 62/100. The 60/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will RXO stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 84/100 for RXO right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this RXO rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-05. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores RXO continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, RXO included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.